MetaCap

Gain Therapeutics (GANX) vs Rallybio (RLYB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rallybio (RLYB) has outperformed Gain Therapeutics (GANX) over the past year, gaining 208.4% versus a loss of 62.4%. Over five years, RLYB leads with a -85.3% price change compared with -87.3% for GANX. Gain Therapeutics is the larger company by market cap ($44.5 million vs $43.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GANX-62.43%RLYB+208.41%
+259%+89%-80%
Nov 21, 20251 yearNov 20, 2026
GANX-87.92%RLYB-85.73%
+13%-45%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GANX versus RLYB key metrics
MetricGANXRLYB
Share price$0.9994$15.47
Market cap$44.50M$43.32M
1-day change-4.82%-0.32%
YTD return-68.96%+181.89%
1-year return-62.43%+208.41%
5-year return-87.27%-85.29%
P/E ratio (TTM)—3.36
EPS (TTM)$-0.42$4.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$858.00K
Revenue growth (YoY)—+34.91%
Net income (latest FY)$-20.16M$-8.98M
Operating margin—-3853.61%
Net margin—-1046.39%
52-week high$4.34$35.15
52-week low$0.94$7.34
Distance from 52-week high-76.97%-55.99%
Analyst consensusstrong_buy—
Avg. price target upside+620.43%—
Average volume550.22K10.14K
Shares outstanding44.53M2.80M
Employees207
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RLYB has outperformed GANX by 270.8 percentage points over the past year.

About Gain Therapeutics

GANX stock →

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

About Rallybio

RLYB stock →

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

GANX vs RLYB FAQ

Which is bigger, Gain Therapeutics or Rallybio?

Gain Therapeutics (GANX) is larger, with a market capitalization of $44.50M compared with $43.32M for Rallybio (RLYB).

Which stock has performed better over the past year, GANX or RLYB?

RLYB returned +208.41% over the past 12 months, compared with -62.43% for GANX (price return, excluding dividends). Past performance does not predict future results.

Are Gain Therapeutics and Rallybio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons